#ICYMI the @ASH_hematology Annual Meeting is around the corner! If you're a trainee who may be attending for the first time, big conferences can seem overwhelming.
In this week's ep., we again team up with the #ASH Trainee Council to chat about how best to navigate the meeting!
Young adults with lung cancer and the people who love you: our first Young Lung Cancer Program patient forum starts tomorrow.
Free, virtual, and zero parking fees 😉
Great news for patients with HR+/HER2- metastatic breast cancer! How many times have we had to update this treatment algorithm in 2026? Oral SERDs are increasingly an option for patients with ESR1-mutated disease. #bcsm@DFCI_BreastOnc
These kinds of surveys are based on a false assumption that there is a specific optimal sequence of treatment in advanced, ER+ breast cancer. The better metaphor is of a buffet table. You are going to have the chance to try everything, and the sequence of treatment is dictated by what appeals at the moment based on clinical cancer burden, prior therapy, biomarkers (to some degree), and treatment logistics/safety/tolerability profile.
Every clinician knows this.
We should resist the KOL- and pharma-driven desire to specify a treatment plan in the absence of any data, absence of studies comparing one in-class drug versus another, absence of studies designed to test real sequences of treatment vs generating FDA approvals.
👏🙌🏻 In just 6½ months, 12 FDA-approved breast cancer treatment indications, 10 for advanced/metastatic disease!
4 newly approved drugs + 8 new or expanded indications for existing therapies.
After years of waiting for more options, we’re seeing research translate into meaningful progress. Now we need to accelerate advances for #TNBC/#mTNBC, where significant unmet needs remain! #bcsm
This is the treatment algorithm we have used during our discussion with @NiuSanford and @MadhuEluri for #RectalCancer
- In PROSPECT study, selectively XRT was avoided.
- In AZUR-01, selectively surgery (and Chemo) was avoided.
#OncTwitter#gism@OncUpdates
Exciting news! Today the FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. First approval for giredestrant!! FDA.gov. @OncoAlert@OncBrothers
65yo patient with de-novo, HR+/HER2- MBC (bone, lymph nodes).
After 2 years on letrozole + ribociclib, she develops two new small liver mets, biopsy confirmed ER+ mBC. No symptoms, normal LFTs.
ctDNA shows ESR1 and PIK3CA mutations.
What would you prescribe next?
Based on evERA trial, Giredestrant (oral SERD) + everolimus is now @FDA ✅ for HR+ mESR1 #breastcancer HR+ after CDK4/6i + ET:
- ⬆️ PFS2: 19.02mos vs. 13.7mos (HR: 0.69)
- Improved chemo-free survival: 11.1mos vs. 7.9 mos (HR: 0.61)
- More options in mESR1
#OncTwitter#bcsm
Always a pleasure w the best sibling duo in oncology!
Rectal cancer continues to pave the way for organ preservation & targeted therapies (including IO) among GI cancers.
Tune in for our thoughts & let us know any feedback.